Anavex Life Sciences Corp (AVXL)

[falconer66a]

But a love of what sort?

AVXL needs some love from the big boys on Wall Street(think SAVA, ANVS).

Well, that would be nice. But affections from market movers who claim Wall Street as their venue are of significance only before the big, final clinical results are released from any one of the three on-going blarcamesine clinical trials. Instead of love, those data will move the AVXL share price.

Most likely, the Rett results will appear first, with data points that validate the unique mechanism of action (MOA) of blarcamesine, operating in nerve cells; against a heretofore un-treatable central nervous system disease.

But, of course, the Anavex naysayers of every stripe will note (well TELL us) that Rett syndrome is but a rare genetic disease of little girls. Nice, but of no real investment significance (it will be claimed).

Then, it will be the Parkinson’s disease dementia study. Profound results, there, too. But, of course, the very first thing that we will be warned about is that “It was NOT a study of real Parkinson’s disease, just a less common, less significant sub-type. Not really important.”

Then, finally, it will be the big Alzheimer’s results. Like the others, they will be profound; game-changing for Alzheimer’s sufferers. The Anavex naysayers, finally, will be silenced. Nothing they can say. FDA or TGA (Australian Therapeutic Goods Administration) approval of the drug will quickly follow. The AVXL share price will continue the ascent begun with the Rett results.

Long-suffering patience is required—for both AVXL shareholders and those with the CNS diseases Anavex is targeting (and will treat).